Beam Therapeutics
BEAM · NASDAQ
$24.93+$0.74 (+3.06%)TodayMarket closed ·
Prev close $24.19
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 26.4% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- -$1.17
- Revenue estimate
- $10.18M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$1.13 | -$1.18 | −4.6% |
| Q1 FY26 | -$1.12 | -$0.91 | +18.6% |
| Q4 FY25 | -$1.01 | -$0.103 | +89.8% |
| Q3 FY25 | -$1.06 | -$1.10 | −3.7% |
| Q2 FY25 | -$1.13 | -$1.00 | +11.7% |
| Q1 FY25 | -$1.23 | -$1.24 | −0.8% |
| Q4 FY24 | -$1.23 | -$1.09 | +11.3% |
| Q3 FY24 | -$1.18 | -$1.17 | +0.8% |
Earnings calls
- Citigroup’s Biopharma Back to School Summit 2026
- Special Call - Beam Therapeutics Inc.
- RBC Capital Markets Global Healthcare Conference 2026
- Special Call - Beam Therapeutics Inc.
- BEAM - Earnings call Q4 2025
- 44th Annual J.P. Morgan Healthcare Conference
- H.C. Wainwright 27th Annual Global Investment Conference
- Wells Fargo 20th Annual Healthcare Conference 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.